date,title,source
Nov-13-18,"Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer",GlobeNewswire
Dec-03-18,What Kind Of Shareholders Own Veru Inc (NASDAQ:VERU)?,Simply Wall St.
Dec-03-18,Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil  Finasteride Tablet for Benign Prostatic Hyperplasia,GlobeNewswire
Dec-13-18,Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter,GlobeNewswire
Jan-14-19,Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia,GlobeNewswire
Jan-15-19,Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019,GlobeNewswire
Jan-18-19,"Before You Buy Veru Inc. (NASDAQ:VERU), Consider Its Volatility",Simply Wall St.
Jan-22-19,"Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer",GlobeNewswire
Feb-06-19,Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline,Zacks
Feb-06-19,"Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th",GlobeNewswire
Feb-12-19,Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium,GlobeNewswire
Feb-13-19,Veru Reports Strong Fiscal 2019 First Quarter Financial Results,GlobeNewswire
Mar-06-19,Have Insiders Been Buying Veru Inc. (NASDAQ:VERU) Shares This Year?,Simply Wall St.
Mar-12-19,Veru to Participate in Two Investor Conferences in March,GlobeNewswire
